Literature DB >> 27594153

Clinical Features of 32 Patients with XO/XY Gonadal Dysgenesis.

Jian-Fa Jiang1, Qin-Jie Tian1, Wei Xue1, Yan Deng1, Ting-Ping Zheng1, Ai-Jun Sun1.   

Abstract

Objective To summarize the clinical features of XO/XY gonadal dysgenesis. Method We retrospectively analyzed the clinical data of patients with XO/XY gonadal dysgenesis admitted to Peking Union Medical College Hospital from January 2008 to May 2015. Results Totally 32 patients with XO/XY gonadal dysgenesis were included. The social gender was female in all subjects and the age 6 to 33 years. Patients presented mainly with primary amenorrhea or short stature,and usually had specific somatic signs of Turner's syndrome. The breast development of 27 patients (84.38%) was less than level 3. The armpit hair was sparse or absent in 28 patients (87.5%) and the pubic hair was sparse or absent in 26 patients (81.25%).Other findings include naive vulva (n=18,56.25%)) and enlarged clitoris (n=5,15.63%). The average level of follicle stimulating hormone was (78.56±35.62) mIU/ml,the luteinizing hormone level was (20.23±11.35) mIU/ml,the estradiol level was (9.94±8.21) pg/ml,and the testosterone level was (0.24±0.18) ng/ml. All patients received prophylactic gonadectomy. The histopathology results showed a variety of gonads,and gonadal malignancy were observed in 4 patients.Conclusions Patients with XO/XY gonadal dysgenesis manifest primary amenorrhea or short stature,poorly developed secondary sexual characteristics,and elevated gonadotropin level. The gonads have increased risk of gonadal malignancy.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27594153     DOI: 10.3881/j.issn.1000-503X.2016.04.008

Source DB:  PubMed          Journal:  Zhongguo Yi Xue Ke Xue Yuan Xue Bao        ISSN: 1000-503X


  1 in total

1.  Growth data and tumour risk of 32 Chinese children and adolescents with 45,X/46,XY mosaicism.

Authors:  Lili Pan; Zhe Su; Jianming Song; Wanhua Xu; Xia Liu; Longjiang Zhang; Shoulin Li
Journal:  BMC Pediatr       Date:  2019-05-06       Impact factor: 2.125

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.